Stempeutics Research Pvt. Ltd. applications

Our First DCGI Approved Stem Cell Product: Stempeucel® is the FIRST innovative stem cell based biological product to be approved by DCGI (Indian FDA) for manufacturing and marketing for the treatment of Critical Limb Ischemia (CLI). Stempeucel® product has been licensed to Cipla in India. Stempeutics is seeking partnership for further clinical development and commercialization of Stempeucel® for Global markets.

Stempeucel® shown anti-inflammatory, immunomodulatory and chondrogenic properties at key stages of development

Anti-inflammatory, angiogenic and wound healing properties of MSCs are key to successfully treat patients with DFU

Stempeucel® can reduce inflammation, which allows the tissues around the fistula tract to heal

Phase 3 study assessing the Efficacy and Safety of Stempeucel® in Patients with Moderate to Severe ARDS due to COVID 19